Combination of | |
---|---|
Telmisartan | Angiotensin II receptor antagonist |
Hydrochlorothiazide | Thiazide diuretic |
Clinical data | |
Trade names | MicardisPlus, Micardis HCT, PritorPlus, others |
AHFS/ Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C40H38ClN7O6S2 |
Molar mass | 812.36 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Telmisartan/hydrochlorothiazide, sold under the brand name Micardis HCT among others, is a fixed-dose combination medication used to treat high blood pressure. [2] It is a combination of telmisartan an angiotensin II receptor antagonist with hydrochlorothiazide a diuretic. [2] It may be used if telmisartan by itself is not sufficient. [5] It is taken by mouth. [5]
Common side effects include dizziness, upper respiratory tract infections, nausea, diarrhea, and tiredness. [2] Severe side effects may include kidney problems, electrolyte problems, and allergic reactions. [2] Use during pregnancy may harm the baby. [2] Telmisartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the kidneys' ability to retain water. [2]
The combination was approved for medical use in the United States in November 2000, [6] [7] and in the European Union in April 2002. [3] [4] The combination is on the World Health Organization's List of Essential Medicines. [8] It is available as a generic medication. [5]